Stephane Champiat, MD PhD

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Poster(s):

• (P 431) INVOKE: A PHASE 1 STUDY OF OKN4395, A FIRST-IN-CLASS EP2/EP4/DP1 TRIPLE PROSTANOID RECEPTOR ANTAGONIST, IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING SARCOMAS